5
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Machine Learning-Assisted Screening of Herbal Medicine Extracts as Vaccine Adjuvants

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Adjuvants are important vaccine components, composed of a variety of chemical and biological materials that enhance the vaccine antigen-specific immune responses by stimulating the innate immune cells in both direct and indirect manners to produce a variety cytokines, chemokines, and growth factors. It has been developed by empirical methods for decades and considered difficult to choose a single screening method for an ideal vaccine adjuvant, due to their diverse biochemical characteristics, complex mechanisms of, and species specificity for their adjuvanticity. We therefore established a robust adjuvant screening strategy by combining multiparametric analysis of adjuvanticity in vivo and immunological profiles in vitro (such as cytokines, chemokines, and growth factor secretion) of various library compounds derived from hot-water extracts of herbal medicines, together with their diverse distribution of nano-sized physical particle properties with a machine learning algorithm. By combining multiparametric analysis with a machine learning algorithm such as rCCA, sparse-PLS, and DIABLO, we identified that human G-CSF and mouse RANTES, produced upon adjuvant stimulation in vitro, are the most robust biological parameters that can predict the adjuvanticity of various library compounds. Notably, we revealed a certain nano-sized particle population that functioned as an independent negative parameter to adjuvanticity. Finally, we proved that the two-step strategy pairing the negative and positive parameters significantly improved the efficacy of screening and a screening strategy applying principal component analysis using the identified parameters. These novel parameters we identified for adjuvant screening by machine learning with multiple biological and physical parameters may provide new insights into the future development of effective and safe adjuvants for human use.

          Related collections

          Most cited references83

          • Record: found
          • Abstract: found
          • Article: found
          Is Open Access

          mixOmics: An R package for ‘omics feature selection and multiple data integration

          The advent of high throughput technologies has led to a wealth of publicly available ‘omics data coming from different sources, such as transcriptomics, proteomics, metabolomics. Combining such large-scale biological data sets can lead to the discovery of important biological insights, provided that relevant information can be extracted in a holistic manner. Current statistical approaches have been focusing on identifying small subsets of molecules (a ‘molecular signature’) to explain or predict biological conditions, but mainly for a single type of ‘omics. In addition, commonly used methods are univariate and consider each biological feature independently. We introduce mixOmics, an R package dedicated to the multivariate analysis of biological data sets with a specific focus on data exploration, dimension reduction and visualisation. By adopting a systems biology approach, the toolkit provides a wide range of methods that statistically integrate several data sets at once to probe relationships between heterogeneous ‘omics data sets. Our recent methods extend Projection to Latent Structure (PLS) models for discriminant analysis, for data integration across multiple ‘omics data or across independent studies, and for the identification of molecular signatures. We illustrate our latest mixOmics integrative frameworks for the multivariate analyses of ‘omics data available from the package.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway.

            The presence of DNA in the cytoplasm of mammalian cells is a danger signal that triggers host immune responses such as the production of type I interferons. Cytosolic DNA induces interferons through the production of cyclic guanosine monophosphate-adenosine monophosphate (cyclic GMP-AMP, or cGAMP), which binds to and activates the adaptor protein STING. Through biochemical fractionation and quantitative mass spectrometry, we identified a cGAMP synthase (cGAS), which belongs to the nucleotidyltransferase family. Overexpression of cGAS activated the transcription factor IRF3 and induced interferon-β in a STING-dependent manner. Knockdown of cGAS inhibited IRF3 activation and interferon-β induction by DNA transfection or DNA virus infection. cGAS bound to DNA in the cytoplasm and catalyzed cGAMP synthesis. These results indicate that cGAS is a cytosolic DNA sensor that induces interferons by producing the second messenger cGAMP.
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              Toll-like Receptors and the Control of Immunity

                Bookmark

                Author and article information

                Contributors
                Journal
                Front Immunol
                Front Immunol
                Front. Immunol.
                Frontiers in Immunology
                Frontiers Media S.A.
                1664-3224
                19 May 2022
                2022
                : 13
                : 847616
                Affiliations
                [1] 1Division of Vaccine Science, Department of Microbiology and Immunology, International Vaccine Design Center (vDesC), The Institute of Medical Science, The University of Tokyo (IMSUT) , Tokyo, Japan
                [2] 2Laboratory of Mockup Vaccine, Center for Vaccine and Adjuvant Research Center (CVAR), National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN) , Osaka, Japan
                [3] 3Laboratory of Bioinformatics, Artificial Intelligence Center for Health and Biomedical Research, National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN) , Osaka, Japan
                [4] 4Research Center for Medicinal Plant Resources, National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN) , Ibaraki, Japan
                [5] 5Department of Immunology, Hyogo College of Medicine , Hyogo, Japan
                [6] 6Division of Malaria Immunology, Department of Microbiology and Immunology, International Vaccine Design Center (vDesC), The Institute of Medical Science, The University of Tokyo (IMSUT) , Tokyo, Japan
                [7] 7Immunology Frontier Research Center (IFReC), Osaka University , Osaka, Japan
                Author notes

                Edited by: Lee Mark Wetzler, Boston University, United States

                Reviewed by: Nikunj M Shukla, University of California, San Diego, United States; Inger Øynebråten, Oslo University Hospital, Norway

                *Correspondence: Ken J. Ishii, kenishii@ 123456ims.u-tokyo.ac.jp

                This article was submitted to Vaccines and Molecular Therapeutics, a section of the journal Frontiers in Immunology

                Article
                10.3389/fimmu.2022.847616
                9160479
                35663999
                9bbaaefe-cc84-4563-a30c-c5ddff183911
                Copyright © 2022 Hioki, Hayashi, Natsume-Kitatani, Kobiyama, Temizoz, Negishi, Kawakami, Fuchino, Kuroda, Coban, Kawahara and Ishii

                This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

                History
                : 03 January 2022
                : 30 March 2022
                Page count
                Figures: 6, Tables: 1, Equations: 0, References: 83, Pages: 19, Words: 10235
                Funding
                Funded by: Japan Agency for Medical Research and Development , doi 10.13039/100009619;
                Funded by: Japan Science and Technology Corporation , doi 10.13039/501100001695;
                Categories
                Immunology
                Original Research

                Immunology
                vaccine,adjuvant,machine learning,herbal extracts,mouse,human
                Immunology
                vaccine, adjuvant, machine learning, herbal extracts, mouse, human

                Comments

                Comment on this article